Sotera Health Company $SHC Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Sotera Health Company (NASDAQ:SHC) by 7.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 470,803 shares of the company’s stock after purchasing an additional 33,221 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.16% of Sotera Health worth $8,357,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. CenterBook Partners LP boosted its position in Sotera Health by 94.1% during the fourth quarter. CenterBook Partners LP now owns 151,529 shares of the company’s stock worth $2,673,000 after acquiring an additional 73,473 shares during the last quarter. Militia Capital Management LLC acquired a new position in Sotera Health in the 1st quarter valued at $3,877,000. Geode Capital Management LLC raised its holdings in Sotera Health by 13.8% in the 4th quarter. Geode Capital Management LLC now owns 3,931,834 shares of the company’s stock valued at $69,372,000 after acquiring an additional 476,365 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Sotera Health by 13.4% during the 1st quarter. Bank of New York Mellon Corp now owns 1,403,971 shares of the company’s stock worth $20,133,000 after purchasing an additional 166,055 shares during the period. Finally, Balefire LLC acquired a new stake in shares of Sotera Health during the first quarter worth $1,476,000. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Stock Performance

SHC stock opened at $18.90 on Tuesday. The company has a market cap of $5.39 billion, a price-to-earnings ratio of 33.16 and a beta of 1.77. The company has a quick ratio of 2.55, a current ratio of 2.80 and a debt-to-equity ratio of 3.33. The business has a fifty day simple moving average of $18.38 and a 200-day simple moving average of $16.48. Sotera Health Company has a 52 week low of $13.09 and a 52 week high of $19.85.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The firm had revenue of $321.38 million for the quarter, compared to analysts’ expectations of $309.70 million. During the same quarter last year, the firm earned $0.20 earnings per share. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, equities research analysts expect that Sotera Health Company will post 0.86 EPS for the current year.

Insider Transactions at Sotera Health

In other news, insider Michael P. Rutz sold 150,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $18.84, for a total value of $2,826,000.00. Following the transaction, the insider directly owned 334,279 shares in the company, valued at $6,297,816.36. This trade represents a 30.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of Sotera Health stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the transaction, the chairman directly owned 3,969,393 shares in the company, valued at $73,433,770.50. This represents a 17.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 1,294,515 shares of company stock worth $23,999,528. Company insiders own 15.36% of the company’s stock.

Analyst Ratings Changes

SHC has been the subject of a number of recent analyst reports. Citigroup lifted their price objective on Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. increased their target price on Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Piper Sandler restated an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of Sotera Health in a report on Friday, August 7th. Wall Street Zen raised shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 29th. Finally, The Goldman Sachs Group started coverage on shares of Sotera Health in a report on Friday, June 5th. They set a “buy” rating and a $20.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Sotera Health currently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Sotera Health Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.